Cancer and Tyrosine Kinase Inhibition
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Motivation (1)
 In first world countries cancer is the second most common cause of death after cardiovascular diseases.  For most tumors, treatment is limited to surgery, radiation, or chemotherapy.
• Radiation and chemotherapy have high toxicity and serve as a treatment when no other option can be found.
 More research is needed to identify the causes of cancer at the molecular level so that more effective therapies can be developed.
Motivation (2)
 Fighting cancer at the molecular level:
• In this unit we examine a promising approach to molecular cancer therapeutics.
• The target proteins of these therapies will provide running examples for the rest of the course.
 The study of these proteins is very interesting from a structural bioinformatics perspective.  Lots of data! The PDB contains many structures that are protein targets or are enzymes that interact with these targets.
 Understanding the structure/function dependencies will require that you recall several topics from earlier courses, for example: exon splicing, post-translational modification, domain interactions, cellular localization, etc.
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Introduction (1)
 Neoplasms (new growth) may be benign or malignant.
• Benign tumors are usually localized and not harmful.
• Malignancies are characterized by autonomous cell proliferation and possibly metastatic behavior.
 Autonomous: proliferation without regulation  Metastatic: the ability to travel and invade other (different) tissues.
 Lack of regulation of proliferation may be due to aberrant behavior of signaling molecules.
• Normally, cell proliferation is controlled by a complicated series of events involving interactions between signal proteins and other molecules.
Introduction (2)
 Signaling molecules include the tyrosine kinases.
• They are involved in both normal and abnormal cell proliferation.
• A tyrosine kinase is an enzyme that catalyzes the phosphorylation of some particular tyrosine residue in a target protein.
 Phosphorylation controls many cellular processes:
 progression through the cell cycle
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Introduction (3)
 Tyrosine kinase functionality
• Phosphorylation: A kinase can transfer a phosphate group from ATP to a tyrosine residue.
• This is important as one of the mechanisms for signal transmission within a cell.
Introduction (4)
 Phosphorylation can produce a change in conformation:
Kinase Facts
• There are 518 known kinases in the human genome.
 About 2% of all genes encode for kinases.
• The average sequence identity for any two kinases is about 30% in the catalytic domain.
• More than 90 tyrosine kinases are known.
 More than half of these are transmembrane receptors.  The rest are cytoplasmic non-receptors.  You can think of tyrosine kinases as "relay points" for signal pathways in the cell.  The cytoplasmic group includes nuclear kinases.
 We will focus on the c-Abl (Abelson) nuclear tyrosine kinase.
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The c-Abl Tyrosine Kinase  The Abelson tyrosine kinase (c-Abl) is localized at several sites within the cell.
• Sites include: nucleus, cytoplasm, mitochondria, and endoplasmic reticulum.
 c-Abl interacts with several cellular proteins:
• For example: cell-cycle regulators, cytoskeletal proteins, kinases, phosphatases, signaling adaptors, and transcription factors.
 c-Abl is involved with various cellular processes including: regulation of cell growth, DNA-damage response, and cell migration.
Tyrosine Kinase Inhibition 9
c-Abl Regulation  Because of these important functional roles in the cell it is necessary that c-Abl is precisely controlled with respect to both its localization and timing of kinase activity.
• We start by reviewing the normal structure of c-Abl and then consider aberrant structure leading to cancer.
Normal Generation of c-Abl
 The generation of a normal c-Abl protein requires three final steps:
1. N-terminal methionine removal by means of methionine aminopeptidase (MetAP or MAP). 2. Myristoylation by means of N-myristoyltransferase (Nmt). 3. The myristoyl group interacts with the kinase domain to help provide regulation by autoinhibition.
More details on the next three slides:
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1) c-Abl Methionine Removal
• MAP operates on the N-terminal of the nascent protein, removing the methionine residue before the protein is fully formed (Selmer & Liljas, 2008) .
• N-myristoylation is the attachment of a 14-carbon fatty acid (called myristate) onto the N-terminal glycine residue of a target protein. • N-myristoyltransferase (Nmt) with myristoyl-CoA:
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3) Autoinhibition by the myristoyl group (1)
• Myristoylation is often used for protein localization, the myristoyl group providing an anchor within a cell membrane.
• In the case of Abl, the group is inserted into a pocket of Abl and this insertion acts as an inhibitor. 3) Autoinhibition by the myristoyl group (2) • The residues upstream from the myristoyl group cannot be resolved by the x-ray analysis.
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Myristoyl group added by Nmt Abl tyrosine kinase PDB id:1OPK
Chronic Myelogenous Leukemia
 CML is a cancer of the white blood cells.
• Incidence is about 3 per 200,000 people (5000 new cases each year in the U.S.A.).
• It represents about 17% of all cases of adult leukemia.
• It can be induced by exposure to ionizing radiation.
 At the molecular level, the most common cause of CML relates to the formation of an Abelson tyrosine kinase that does not have the autoinhibitory myristoyl group.
• How does this happen?
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CML is Caused by an Oncogene
• About 95% of CML cases are due to a chromosomal abnormality caused by a reciprocal translocation between chromosome 9 and 22:
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The Bcr-Abl Fusion Protein
• Expression of the oncogene leads to the formation of Bcr-Abl, a fusion protein that does not have the myristoylated N-terminus.
 No myristoyl group  no auto-inhibition and so the protein becomes constitutively active (i.e. it works without activation signals from other proteins). 
Therapy for CML
• About 15 years ago, Novartis developed a drug called imatinib mesylate also known as Gleevec (in the USA) or Glivec (in the UK).
• Imatinib is designed to interact with Bcr-Abl and inhibit its activity (of course, it will also inhibit normal Abl).
• This is an exciting advance in cancer therapy because it acts as "the magic bullet" for a particular cancer.
 Prior to this, chemotherapies involved heavy handed "molecular sledgehammers" that cut back on all rapidly proliferating cells.
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Imatinib Mesylate
• Even though Abl is structurally similar to other kinases, imatinib shows a strong preference for Abl with very few side-effects.
The New Paradigm  Imatinib and similar drugs have saved thousands of lives.
• They do not cure the cancer but make it more manageable.
 Patients stay on the drug for the remainder of their lives.  There is the possibility that a mutation in the Philadelphia oncogene produces a fusion protein that is resistant to imatinib.
 Research is now underway to find more kinase targets that will yield to inhibitory drugs.
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More Molecular Therapies for Cancer? (1)  Can this success story be repeated for other cancers? Hopefully: Yes, but CML has attributes that make it an easy candidate for therapeutic intervention.
• The correlation between CML and a particular malformed protein is very high.
 Some cancers do not have such an obvious cause.  For example, AML (Acute Myeloid Leukemia) is a heterogeneous disease: mutations can occur in any of several tyrosine kinases.
More Molecular Therapies for Cancer? (2) • Mutations giving gain of function are easier to correct than mutations giving loss of function.
 Bcr-Abl is a fusion protein that results in overactive functionality. The corrective therapy requires an inhibitor.  Mutations in a tumor suppressor protein (such as p53) cause loss of function. The corrective therapy requires restoration of functionality. This is a much harder problem.
• Specificity of inhibition is crucial.
 Researchers were surprised to find that imatinib binds almost exclusively with Abl and Bcr-Abl even though these kinases have high sequence similarity to other kinases.
 So, there are relatively few side effects (for adults).  Exposure to imatinib during pregnancy carries an increased risk of serious fetal abnormalities or spontaneous abortion.
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